Frontier Biotechnologies (SHA:688221) will conduct a phase II clinical trial of the drug Aconin for additional indication after receiving the Chinese drug administration's approval, according to a Shanghai Stock Exchange disclosure on Saturday.
The drug will be tested as a treatment of incomplete immune reconstitution in HIV-1 infected patients who are receiving stable antiretroviral therapy and have achieved virological suppression, the biotechnology company said.
The company's shares closed more than 4% higher.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。